Aptar Reports Third Quarter 2023 Results
*Reported sales increased 7% and net income increased 55% to $84 million *Core sales increased 2% and adjusted EBITDA of $193 million increased 26% from the prior year *Pharma proprietary drug delivery systems had double-digit growth across multiple therapeutic applications *Beauty’s prestige and mass fragrance dispensing technologies had double-digit sales growth *Reported earnings per share increased about 56% to $1.26 compared to $0.81 in the prior year *Adjusted earnings per share increased 39% to $1.39 compared to $1.00 in the prior year (including comparable exchange rates) *Margins continued to expand across all three segments *Cash flow from operations was $173 million and free cash flow was $97 million, up from $55 million in 2022, a 76% increase